首页> 外文期刊>Brachytherapy >Reirradiation of the eye with plaque brachytherapy: A single institution experience report of eight consecutive patients submitted to retreatment after local relapse of malignant disease of the eye
【24h】

Reirradiation of the eye with plaque brachytherapy: A single institution experience report of eight consecutive patients submitted to retreatment after local relapse of malignant disease of the eye

机译:斑块近距离放射疗法对眼睛的再照射:单机构经验报告,局部恶性眼部疾病复发后连续接受治疗的八名患者

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: To evaluate the feasibility of reirradiation of the eye with plaque brachytherapy (REPBT) for local recurrence (LR) of malignant disease of the eye as an alternative to enucleation or other local salvage treatments. Methods and Materials: It was performed a retrospective analysis of all patients who underwent REPBT for LR. The main parameters evaluated were local control and progression-free survival, besides the toxicity profile. Results: There were eight patients who underwent REPBT, seven due to uveal melanoma and one due to retinoblastoma. The median time between the first plaque brachytherapy and the salvage plaque brachytherapy was 24 months (8-49 months). After a median followup of 30 months (8-70 months), the actuarial 2-year local control and progression-free survival was 87.5% and 60%, respectively. All patients evolved with worsening of the visual acuity and cataract. Other complications observed were maculopathy (two patients) and glaucoma (one patient). Conclusions: REPBT should be considered as an option for salvage therapy of LR of malignant disease of the eyes as it provides a high probability of tumor control and eye preservation without compromising disease-free survival.
机译:目的:评估斑块近距离放射疗法(REPBT)对眼睛恶性疾病的局部复发(LR)进行再照射的可行性,以替代摘除术或其他局部抢救治疗。方法和材料:对所有接受REPBT LR治疗的患者进行了回顾性分析。评估的主要参数是局部控制和无进展生存期,以及毒性分布。结果:8例患者行REPBT,7例因葡萄膜黑色素瘤而1例因视网膜母细胞瘤。第一次斑块近距离放射治疗与挽救性斑块近距离放射治疗之间的中位时间为24个月(8-49个月)。中位随访30个月(8-70个月)后,精算2年局部控制和无进展生存率分别为87.5%和60%。所有患者的视力和白内障恶化。观察到的其他并发症是黄斑病(两名患者)和青光眼(一名患者)。结论:REPBT应该被认为是挽救LR的恶性眼病的一种选择,因为它在不损害无病生存期的情况下提供了很高的肿瘤控制和护眼​​率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号